Background: Hairy cell leukemia commonly presents with pancytopenia, indolent course, and predisposition as infectious complications. Current first-line therapeutic options are purine analogues, particularly cladribine, with a high percentage of complete responses and durable remissions. However, their use is poorly investigated in patients affected by severe chronic renal insufficiency. Case presentation: Here, we describe a case of HCL in a 68-year-old man affected by multiple comorbidities, including severe chronic renal failure. After a course of interferon-α, the patient received therapy with Cladribine every other week, obtaining a complete hematological remission and improvement of renal function. Discussion: With a different soft schedule of cladribine, the patient was treated adequately, obtaining a complete remission. Conclusion: Cladribine can be administered with caution, even in patients with renal failure, with good results. Copyright© Bentham Science Publishers
Gozzetti, A., Bacchiarri, F., Raspadori, D., Sicuranza, A., Sammartano, V., Bocchia, M. (2023). Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency. REVIEWS ON RECENT CLINICAL TRIALS, 18(4), 300-303 [10.2174/0115748871241817230919062313].
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency
Gozzetti, Alessandro;Bacchiarri, Francesca;Raspadori, Donatella;Sicuranza, Anna;Sammartano, Vincenzo;Bocchia, Monica
2023-01-01
Abstract
Background: Hairy cell leukemia commonly presents with pancytopenia, indolent course, and predisposition as infectious complications. Current first-line therapeutic options are purine analogues, particularly cladribine, with a high percentage of complete responses and durable remissions. However, their use is poorly investigated in patients affected by severe chronic renal insufficiency. Case presentation: Here, we describe a case of HCL in a 68-year-old man affected by multiple comorbidities, including severe chronic renal failure. After a course of interferon-α, the patient received therapy with Cladribine every other week, obtaining a complete hematological remission and improvement of renal function. Discussion: With a different soft schedule of cladribine, the patient was treated adequately, obtaining a complete remission. Conclusion: Cladribine can be administered with caution, even in patients with renal failure, with good results. Copyright© Bentham Science PublishersI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1248134